StockData
Atrium Therapeutics, Inc. logo

Atrium Therapeutics, Inc. (RNA) stock

RNANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$6.92−0.06 (-0.86%)

Close on Nov 20, 2026Market cap $118.37MP/E –Yield –

Atrium Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$25.78M–
Q2 FY2026Jun 30, 2026-$3.96M–
Q1 FY2026Mar 31, 2026-$33.24M–
Q3 FY2025Sep 30, 2025$833.00K–
Q2 FY2025Jun 30, 2025-$12.17M–
Q1 FY2025Mar 31, 2025-$11.10M–

More Atrium Therapeutics figures

See a number that looks wrong?